Arcutis Biotherapeutics (ARQT) Expected to Announce Earnings on Wednesday

Key Points

• Q1 2026 earnings expected after the close on May 6 with analysts forecasting EPS of ($0.03) and revenue of $102.21 million; the earnings call is scheduled for 4:30 PM ET.
• In the prior quarter (reported Feb. 25) Arcutis beat estimates with EPS of $0.13 vs. $0.03 expected and revenue of $129.5M, and Wall Street's consensus is a "Moderate Buy" with an average target of $34 and expectations of $0 EPS this year and $1 next year.
• Insiders sold 159,546 shares totaling about $4.03 million over the last three months (insiders still own 9.4%), while institutional activity shows modest new and increased positions.

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) is anticipated to post its Q1 2026 results after the market closes on Wednesday, May 6th. Analysts expect Arcutis Biotherapeutics to post earnings of ($0.03) per share and revenue of $102.2120 million for the quarter. Individuals may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Wednesday, May 6, 2026 at 4:30 PM ET.

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last issued its earnings results on Wednesday, February 25th. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.03 by $0.10. Arcutis Biotherapeutics had a negative return on equity of 10.26% and a negative net margin of 4.29%.The business had revenue of $129.50 million during the quarter, compared to analysts' expectations of $110.79 million. On average, analysts expect Arcutis Biotherapeutics to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Arcutis Biotherapeutics Trading Down 0.6%

Shares of ARQT opened at $23.29 on Wednesday. Arcutis Biotherapeutics has a 1 year low of $12.42 and a 1 year high of $31.77. The company has a current ratio of 3.17, a quick ratio of 2.99 and a debt-to-equity ratio of 0.57. The stock has a 50 day simple moving average of $24.04 and a 200-day simple moving average of $25.71. The stock has a market cap of $2.91 billion, a PE ratio of -166.35 and a beta of 1.76.

Insider Transactions at Arcutis Biotherapeutics

In other Arcutis Biotherapeutics news, insider Todd Watanabe sold 37,349 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $25.18, for a total value of $940,447.82. Following the transaction, the insider directly owned 785,957 shares in the company, valued at approximately $19,790,397.26. This trade represents a 4.54% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Howard G. Welgus sold 10,000 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $25.05, for a total value of $250,500.00. Following the completion of the transaction, the director owned 59,744 shares in the company, valued at $1,496,587.20. The trade was a 14.34% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders sold 159,546 shares of company stock worth $4,032,162. Corporate insiders own 9.40% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Global Retirement Partners LLC bought a new position in Arcutis Biotherapeutics in the 4th quarter valued at $35,000. NewEdge Advisors LLC boosted its position in Arcutis Biotherapeutics by 209.0% in the 4th quarter. NewEdge Advisors LLC now owns 1,545 shares of the company's stock valued at $45,000 after buying an additional 1,045 shares during the last quarter. Truvestments Capital LLC boosted its position in Arcutis Biotherapeutics by 114.2% in the 4th quarter. Truvestments Capital LLC now owns 3,012 shares of the company's stock valued at $87,000 after buying an additional 1,606 shares during the last quarter. Cibc World Markets Corp bought a new position in Arcutis Biotherapeutics in the 4th quarter valued at $211,000. Finally, Brooklyn Investment Group bought a new position in Arcutis Biotherapeutics in the 4th quarter valued at $239,000.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on ARQT shares. Mizuho dropped their price target on Arcutis Biotherapeutics from $37.00 to $35.00 and set an "outperform" rating for the company in a report on Monday, March 2nd. TD Cowen raised their price target on Arcutis Biotherapeutics from $30.00 to $35.00 and gave the company a "buy" rating in a report on Thursday, February 26th. HC Wainwright raised their price target on Arcutis Biotherapeutics from $30.00 to $34.00 and gave the company a "buy" rating in a report on Thursday, February 26th. Guggenheim raised their price target on Arcutis Biotherapeutics from $34.00 to $35.00 and gave the company a "buy" rating in a report on Friday, February 27th. Finally, Needham & Company LLC raised their price target on Arcutis Biotherapeutics from $31.00 to $36.00 and gave the company a "buy" rating in a report on Thursday, February 26th. Five analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $34.00.

Arcutis Biotherapeutics Company Profile

Arcutis Biotherapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for immuno-inflammatory skin diseases. The company's research and development efforts center on targeted treatments that address the underlying biology of conditions such as plaque psoriasis, atopic dermatitis, seborrheic dermatitis and vitiligo. Arcutis employs a precision-medicine approach to deliver topical therapies designed to improve efficacy and tolerability compared with existing treatment options.

In August 2022, Arcutis received U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.